National Comprehensive Cancer Network

About NCCN

NCCN Flash Update: CORRECTION to the NCCN Chemotherapy Order Templates (MCL17b)

NCCN has published the following correction to the NCCN Chemotherapy Order Templates (NCCN Templates®):

A dosing error that would lead to underdosing of methotrexate was found on the following chemotherapy order template. This error occurred on June 27, 2017 when the chemotherapy order templates were migrated into a new computer program. This template was republished with the correct dosing on August 17, 2017 when the error was discovered.

  • HyperCVAD (Cyclophosphamide/VinCRIStine/DOXOrubicin/Dexamethasone + RiTUXimab (Cycle A) alternating with High-Dose Methotrexate/Cytarabine + RiTUXimab (Cycle B)
    • MCL17b – High-Dose Methotrexate/Cytarabine + RiTUXimab (Cycle B) Course
      • Correct dosing of methotrexate is as follows:
        • Methotrexate
          • 200 mg/m2 over 2 hours on Day 1 followed by
          • 800 mg/m2 IV continuous infusion over 22 hours on Day 1

For the complete updated versions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), NCCN Guidelines® with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Templates®, the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.

Subscribe to NCCN Flash Updates™